Number of pages: 100 | Report Format: PDF | Published date: January 28, 2022
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
According to the deep-dive market assessment study by Growth Plus Reports, the global pediatric neuroblastoma treatment market was valued at US$ 2.20 billion in 2022 and is expected to register a revenue CAGR of 8.9% to reach US$ 5.16 billion by 2031.
Pediatric Neuroblastoma Treatment Market Fundamentals
Pediatric neuroblastoma is a type of cancer that develops in immature nerve cells called neuroblasts. It is the most common solid tumor found in infants and young children, typically occurring in children under the age of five. Neuroblastoma usually starts in the adrenal glands, which are located on top of the kidneys, but it can also form in nerve tissue along the spine, chest, abdomen, or pelvis. The treatment of pediatric neuroblastoma depends on several factors, including the child's age, the stage, and extent of the disease, the presence of certain genetic abnormalities, and the child’s overall health. A multidisciplinary team of healthcare professionals experienced in treating childhood cancers determines the specific treatment plan for pediatric neuroblastoma.
Pediatric Neuroblastoma Treatment Market Dynamics
Neuroblastoma is one of the most common types of childhood cancer, and its incidence has been rising over the years. The growing prevalence of pediatric neuroblastoma creates a demand for effective treatment options, driving pediatric neuroblastoma treatment market growth. According to the National Center for Biotechnology Information, neuroblastoma accounts for around 8-10% of all pediatric cancer cases. The incidence rate of neuroblastoma is 11 to 13 per million children under the age of 15, ranging from 1 per million in children aged 10-14 years old to 65 per million in children under the age of one year. Improved diagnostic methods, such as genetic testing, molecular profiling, and imaging technologies, have enhanced neuroblastoma detection and accurate staging. Early diagnosis allows for timely intervention and targeted treatment, leading to increased pediatric neuroblastoma treatment market demand. Significant advancements have been made in understanding neuroblastoma biology and treatment strategies. Targeted therapies, immunotherapies, and combination treatment regimens have shown promising results in clinical trials and have the potential to improve outcomes for pediatric neuroblastoma patients. The development of novel therapies drives the growth of the pediatric neuroblastoma treatment market. There is a growing focus on precision medicine approaches in treating pediatric neuroblastoma. Advances in genomic profiling and molecular characterization of tumors have identified specific genetic alterations and biomarkers associated with neuroblastoma. This pediatric neuroblastoma treatment industry trend towards personalized treatment approaches is expected to continue, allowing for more tailored and effective therapies. Recognizing pediatric neuroblastoma as a significant health concern has resulted in increased funding from government bodies, nonprofit organizations, and private foundations. These funds support research, clinical trials, and the development of new therapies, fostering market growth.
However, intensive treatments such as high-dose chemotherapy and stem cell transplantation can lead to significant side effects and long-term complications in pediatric neuroblastoma patients. These side effects may impact survivors' quality of life and long-term well-being, which restricts the pediatric neuroblastoma treatment market growth. Neuroblastoma cells can develop resistance to chemotherapy and targeted therapies, leading to treatment failure or disease relapse, which is also expected to hamper the pediatric neuroblastoma treatment market growth.
Pediatric Neuroblastoma Treatment Market Ecosystem
The global pediatric neuroblastoma treatment market is analyzed from four perspectives: treatment type, risk group, end user, and region.
Pediatric Neuroblastoma Treatment Market by Treatment Type
Based on the treatment types, the global pediatric neuroblastoma treatment market is segmented into chemotherapy, immunotherapy, targeted therapy, and others.
The chemotherapy segment accounted for the largest pediatric neuroblastoma treatment market share in 2022, it is expected to register a revenue CAGR of 9.2%. Chemotherapy has been a cornerstone of pediatric neuroblastoma treatment for many years and is considered a standard of care. It is widely used as an initial treatment to shrink tumors before surgery (neoadjuvant chemotherapy) and as a post-surgical treatment to eliminate any remaining cancer cells (adjuvant chemotherapy). It is also used in advanced or metastatic neuroblastoma cases where surgical intervention may not be feasible. Chemotherapy has shown efficacy in reducing tumor size and controlling the spread of neuroblastoma. It is a systemic treatment that can target cancer cells throughout the body, including those that may have spread beyond the primary tumor site. Chemotherapy is often combined with other treatment modalities such as surgery, radiation therapy, and immunotherapy. Combining chemotherapy with these treatments has shown improved outcomes compared to using chemotherapy alone. Chemotherapy is particularly important in treating high-risk neuroblastoma, which is associated with a higher likelihood of relapse and poorer prognosis. Intensive chemotherapy regimens, including high-dose chemotherapy with stem cell transplants, are commonly used in these cases to intensify treatment and improve survival rates. Chemotherapy is a well-established treatment modality with many drugs available for pediatric neuroblastoma. These drugs are generally accessible and have been extensively studied in clinical trials, fueling segmental growth.
Pediatric Neuroblastoma Treatment Market by Risk Group
Based on the risk groups, the global pediatric neuroblastoma treatment market is segmented into low-risk, intermediate-risk, and high-risk.
The high-risk segment accounted for a significant revenue share of the pediatric neuroblastoma treatment market in 2022. High-risk neuroblastoma is characterized by aggressive tumor growth, early metastasis, and a higher likelihood of relapse. These factors contribute to a poorer prognosis compared to low or intermediate-risk neuroblastoma. The urgent need for effective treatment options drives the focus on the high-risk segment. High-risk neuroblastoma accounts for approximately 70% of total neuroblastoma cases globally. High-risk neuroblastoma requires more intensive treatment regimens compared to low or intermediate-risk cases. Intensive chemotherapy, high-dose chemotherapy with stem cell transplant, radiation therapy, and immunotherapy are often utilized to target the aggressive nature of high-risk neuroblastoma. High-risk neuroblastoma has been the focus of extensive research and clinical trials to identify optimal treatment approaches. This research emphasis contributes to the availability of a broader range of treatment options and advancements in the high-risk segment compared to other risk categories. High-risk neuroblastoma has gained significant attention from patient advocacy groups, healthcare organizations, and the general public. The awareness and advocacy efforts contribute to increased funding, research collaboration, and targeted initiatives to improve treatment outcomes for high-risk patients.
Pediatric Neuroblastoma Treatment Market by End User
Based on the end users, the global pediatric neuroblastoma treatment market is segmented into hospitals, cancer specialty centers, and others.
The hospitals segment accounted for the prominent revenue share of the pediatric neuroblastoma treatment market in 2022. Hospitals provide comprehensive care facilities essential for diagnosing, treating, and managing pediatric neuroblastoma. They have the infrastructure, medical equipment, and multidisciplinary teams of healthcare professionals necessary to deliver a range of treatment modalities, including surgery, chemotherapy, radiation therapy, and supportive care. Hospitals often house specialized pediatric oncology departments or cancer centers with expertise in diagnosing and treating pediatric neuroblastoma. These specialized healthcare professionals, including pediatric oncologists, surgeons, radiologists, and radiation oncologists, are crucial in providing the specialized care required for pediatric neuroblastoma patients. Hospitals typically have access to advanced diagnostic and treatment technologies, such as imaging techniques (MRI, CT, PET scans), radiation therapy machines, and surgical facilities. These technologies are crucial for accurate diagnosis, staging, and treatment planning for pediatric neuroblastoma patients.
Pediatric Neuroblastoma Treatment Market by Region
The global pediatric neuroblastoma treatment market has been segmented geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The North America region has the largest pediatric neuroblastoma treatment market size in revenue generation, accounting for around 46.5% market share. Pediatric neuroblastoma has a significant prevalence in the region, which is increasing the demand for pediatric neuroblastoma treatment. According to the American Cancer Society, Neuroblastoma is by far the most frequent malignancy in newborns (those under the age of one year). Each year, approximately 700 to 800 new cases of neuroblastoma are diagnosed in the U.S. North America has a well-developed healthcare infrastructure, including hospitals, specialized pediatric oncology centers, research institutions, and clinical trial networks. This advanced infrastructure provides a strong foundation for diagnosing, treating, and managing pediatric neuroblastoma, attracting patients and healthcare professionals to the region. North America is a hub for research and development in the field of pediatric oncology, including neuroblastoma. Research institutions and academic centers collaborate with pharmaceutical companies, biotechnology firms, and government agencies to drive advancements in treatment options and innovative therapies. North America is at the forefront of technological advancements in healthcare. The region has access to state-of-the-art diagnostic imaging technologies, molecular profiling techniques, and advanced treatment modalities such as targeted therapies, immunotherapies, and precision medicine approaches. The presence of robust healthcare reimbursement systems in North America, such as Medicare and private insurance, provides financial support for pediatric neuroblastoma treatments. Adequate reimbursement mechanisms and insurance coverage reduce the financial burden on patients and their families, enabling broader access to advanced treatments and therapies. The favorable reimbursement framework promotes market growth.
Pediatric Neuroblastoma Treatment Market Competitive Landscape
The prominent players operating in the global pediatric neuroblastoma treatmentmarket are:
Pediatric Neuroblastoma Treatment Market Strategic Developments
Pediatric neuroblastoma is a type of cancer that develops in immature nerve cells called neuroblasts. It is the most common solid tumor found in infants and young children, typically occurring in children under the age of five.
Collaboration and partnerships play a significant role in advancing pediatric neuroblastoma treatment. Key market players collaborate with academic institutions, research organizations, and other industry partners to leverage their expertise, access patient populations, and jointly conduct clinical trials.
The prominent players operating in the global pediatric neuroblastoma treatment Bayer AG, Pfizer Inc, Apeiron Biologics AG, Baxter, and United Therapeutics Corporation.
The global pediatric neuroblastoma treatment market growth is estimated to grow at a revenue CAGR of 8.9% during the forecast period from 2023 to 2031.
The estimated size of the global pediatric neuroblastoma treatment market in 2031 is US$ 5.16 billion.
*Insights on financial performance are subject to the availability of information in the public domain